TMENT SEASE			
	1EQH QUITER 1600/2900	SEP 1 3 2001	

OF E JC	و الموارع a plus sign (+) in	-			`A	oproved for use	e through 10/3	PTO/SB/81 (02	2-01) 0035
0 10 10	Approved for use through 10/31/2002. OMB 0625-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.								
क्ष		Applicatio	Application Number		09/580,018				
CATENT & TR?	E. S.	Filing Date			May 26, 2000				
WI B III	POWED OF A	ATTORNEY OR	First Named Inventor			Dale B. Schenk			
	POWER OF ATTORNEY OR AUTHORIZATION OF AGENT			Title			PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE		
			Group Art Unit			1641			
	1		Examiner	Name		Unassigned.		HDE	
			Attorney D	ocke	t Number	15270J-0	04760US		H
									-
	I hereby appoint: Practitioners at Cu OR Practitioner(s) nar		0				ustomer Bar Code ere		GHN1EH 1600/2900
,		Name			Registra	ition Numbe	r	1	2
1									ğ
•						·· <u>·</u>	ł	1	
•				<u> </u>					1
	as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please change the correspondence address for the above-identified application to: The above-mentioned Customer Number. OR Practitioners at Customer Number								
-									
•	Firm <i>or</i> Individual Name								
•	Address								
1	Address]
	City		S	tate		ZIP]
	Country								
i	Telephone			Fax					
	I am the:	=							\neg

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3167768 v1

NOTE: Signatures of all the inventors or assignées of record of the entire interest or their representative(s) are required.

SIGNATURE of Applicant or Assignee of Record

Name Signature Date

Applicant/Inventor.

*Total of 1 form is submitted.

Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

AUGUST

Neuralab Limited, by: Kevin Insley, Vice President

Submit multiple forms if more than one signature is required, see below*.

31,200/

OPE	Cie	
, 07	Please plus sign (+) inside this box	→ [+
2. SEP .	(A)	
ENT & TR	er the Paperwork Reduction Act of 1995	i, no persons

D pe a più	is sign (·) iii.	side tills box			_		PTO/SB/81 (02-01)	
the Paperv	work Reducti	ion Act of 1995, no person	ns <u>a</u> re re	equired to respond	U.S. Patent and Tra to a collection of inform	pproved for use through 10/3 demark Office; U.S. DEPAR lation unless it displays a val	31/2002. OMB 0651-0035 TMENT OF COMMERCE id OMB control number.	
				Applicati n		09/580,018		
POWER OF ATTORNEY OR AUTHORIZATION OF AGENT		Filing Date		May 26, 2000				
		First Name	d Inventor	Dale B. Schenk				
		Title		PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE				
				Group Art Unit		1641		
				Examiner Name		Unassigned.		
				Attorney Do	ocket Number	15270J-004760US		
I hereby ap	point:							
☐ Practition	ners at Cu	stomer Number			¬	Place Customer Number Bar Code	ľ	
OR		<u></u>	_			Label here		
Practition	ner(s) nan						7]	
)_		Name				ation Number	-	
		Nina M. Asht				37,273	1	
		Jean M. Duv	all			32,731	_[
L		Lisabeth F. Mu	rphy		<u> </u>	1		
Ł					 		.]	
as my/our att	torney(s) o	or agent(s) to prosect	ute the	application ide	ntified above, and	to transact all		
business in t	he United	States Patent and Tr	adem	ark Office conn	ected therewith.			
The abov	e-mention	respondence address ed Customer Numbe stomer Number		ne above-identi	fied application to:	•		
Firm or Individua	I Name							
Address						,		
Address		<u> </u>						
City				St	ate	ZIP		
Country								
Telephone				F	ax			
I am the:								
☐ Applica	nt/Invento	or.					[
Assigne	ee of reco	rd of the entire intere	st. Se	e 37 CFR 3.71				
Stateme	ent under	37 CFR 3.73(b) is en	closec	i. (Form PTO/S	B/96).			
		SIGNA	ATUR	E of Applicant	or Assignee of Re	ecord		
Name	Name Neuralab Limited, by: Kevin Insley, Vice President							
Signature	6 CATERIA							
Date August 31,200/1								
Submit multip	tures of a ole forms	II the inventors or as if more than one sig	ssigne	es of record o	f the entire interes ee below*.	t or their representative	ve(s) are required.	
★Total of *	torm is s	sunmiπed.						

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3167778 v1

RECEIVED

PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Attorney Docket No. 15270J-004760US

STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner: Dale B. Schenk				
Application No./Patent No.: 09/580,018	Filed/Issue Date: May 26, 2000			
Entitled: PREVENTION AND TREATMENT OF AMY	/LOIDOGENIC DISEASE			
Neuralab Limited a	corporation			
	ype of Assignee, e.g., corporation, partnership, university, government agency, etc.)			
states that it is:				
1. the assignee of the entire right, title, and	d interest; or			
2. an assignee of an undivided part interest				
in the patent application/patent identified above by vi	irtue of either:			
A. An assignment from the inventor(s) of the pate recorded in the Patent and Trademark Office a attached.	ent application/patent identified above. The assignment was at Reel, Frame, or for which a copy thereof is			
OR ·				
B. A chain of title from the inventor(s), of the pate shown below:	ent application/patent identified above, to the current assignee as			
From: Dale B. Schenk, Frederique Bard, Theodore Yednock				
The document was recorded in the Unite Reel 011230, Frame 0598, or for which a	d States Patent and Trademark Office at copy thereof is attached.			
 From: <u>Elan Pharmaceuticals, Inc.</u> The document was recorded in the Unite Reel <u>011230</u>, Frame <u>0585</u>, or for which a 	To: Neuralab Limited ad States Patent and Trademark Office at a copy thereof is attached.			
3. From:	То :			
The document was recorded in the Unite	d States Patent and Trademark Office at			
Reel, Frame, or for which a	a copy thereof is attached.			
☐ Additional documents in the chain of title	are listed on a supplemental sheet.			
☐ Copies of assignments or other documents in the [NOTE : A separate copy (i.e., the original assignmust be submitted to Assignment Division in accretorded in the records of the USPTO. See MPE	ment document or a true copy of the original document) ordance with 37 CFR Part 3, if the assignment is to be			
The undersigned (whose title is supplied below) is e	mpowered to sign this statement on behalf of the assignee.			
September / , 2001	160 Atomic			
Date	Signature			
	Kevin Insley			
	Typed or printed name			
	Vice President			
	Title			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.